Teva Pharmaceutical Industries PE Ratio 2006-2018 | TEVA

Current and historical p/e ratio for Teva Pharmaceutical Industries (TEVA) from 2006 to 2018. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Teva Pharmaceutical Industries PE ratio as of November 12, 2018 is 7.38.
Teva Pharmaceutical Industries PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2018-11-12 23.69 0.00
2018-09-30 21.54 $-10.89 0.00
2018-06-30 24.32 $-10.10 0.00
2018-03-31 17.09 $-15.80 0.00
2017-12-31 18.95 $-16.26 0.00
2017-09-30 17.50 $-5.95 0.00
2017-06-30 32.86 $-6.12 0.00
2017-03-31 31.37 $0.02 1568.54
2016-12-31 35.10 $0.07 501.38
2016-09-30 44.14 $1.72 25.66
2016-06-30 47.88 $1.49 32.13
2016-03-31 50.67 $1.92 26.39
2015-12-31 61.79 $1.82 33.95
2015-09-30 52.84 $2.07 25.53
2015-06-30 55.04 $2.97 18.53
2015-03-31 57.70 $3.21 17.97
2014-12-31 52.94 $3.56 14.87
2014-09-30 49.21 $3.21 15.33
2014-06-30 47.68 $3.03 15.74
2014-03-31 47.72 $1.63 29.28
2013-12-31 35.94 $1.50 23.96
2013-09-30 33.63 $1.42 23.69
2013-06-30 34.66 $0.49 70.74
2013-03-31 34.85 $2.01 17.34
2012-12-31 32.57 $2.24 14.54
2012-09-30 35.94 $2.44 14.73
2012-06-30 34.05 $3.56 9.56
2012-03-31 38.70 $3.21 12.06
2011-12-31 34.51 $3.08 11.21
2011-09-30 31.69 $3.36 9.43
2011-06-30 40.86 $3.48 11.74
2011-03-31 42.35 $3.72 11.38
2010-12-31 43.81 $3.67 11.94
2010-09-30 44.18 $3.24 13.64
2010-06-30 43.40 $2.81 15.44
2010-03-31 52.51 $2.51 20.92
2009-12-31 46.64 $2.23 20.91
2009-09-30 41.87 $0.93 45.02
2009-06-30 40.77 $0.98 41.60
2009-03-31 37.12 $1.05 35.35
2008-12-31 34.99 $0.72 48.60
2008-09-30 37.56 $2.29 16.40
2008-06-30 37.49 $2.16 17.36
2008-03-31 37.62 $2.14 17.58
2007-12-31 37.78 $2.38 15.87
2007-09-30 36.08 $2.24 16.11
2007-06-30 33.40 $2.34 14.28
2007-03-31 30.25 $2.30 13.15
2006-12-31 25.06 $0.48 52.22
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $24.090B $22.385B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $55.271B 9.49
Mylan (MYL) United Kingdom $18.532B 7.63
Bausch Health Cos (BHC) Canada $9.165B 6.64
Dr Reddy's Laboratories (RDY) India $5.542B 22.13
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.633B 4.39
Supernus Pharmaceuticals (SUPN) United States $2.334B 22.13
Amphastar Pharmaceuticals (AMPH) United States $0.971B 105.00
Akorn (AKRX) United States $0.845B 0.00
Homology Medicines (FIXX) United States $0.749B 0.00
CymaBay Therapeutics (CBAY) United States $0.624B 0.00
Assembly Biosciences (ASMB) United States $0.581B 0.00
Corium (CORI) United States $0.457B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.443B 0.00
Voyager Therapeutics (VYGR) United States $0.375B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.313B 0.00
Teligent (TLGT) United States $0.165B 0.00
Sol-Gel Technologies (SLGL) Israel $0.131B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.100B 0.00
Aevi Genomic Medicine (GNMX) United States $0.081B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.053B 0.00
Evoke Pharma (EVOK) United States $0.046B 0.00
Acasti Pharma (ACST) Canada $0.045B 0.00
Agile Therapeutics (AGRX) United States $0.031B 0.00
China Pharma Holdings (CPHI) China $0.013B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.009B 0.00